# UCHT1 - Anti-CD3 Monoclonal Antibody
#
# Source: Callard et al. (1981) Clin Exp Immunol
# Patent Status: Expired (1981 publication)
#
# Key features:
# - Murine IgG1 antibody
# - Cross-reacts with chimpanzee but NOT cynomolgus/macaque CD3
# - Alternative epitope to OKT3 (different binding mode)
#
# References:
# - Callard RE, et al. (1981) Clin Exp Immunol 43(3):497-505
# - Zhu Z, Carter P (1995) J Immunol - V9 derivative

name: ucht1
aliases:
  - UCHT-1
  - HuM291  # Humanized version (visilizumab parent)

# Variable region sequences (murine)
vh_sequence: >-
  EVKLDETGGGLVQPGRPMKLSCVASGFTFSDYWMNWVRQSPEKGLEWVAEIRLKSNNYATHYAESVK
  GRFTISRDDSKSSVYLQMNNLRVEDTGIYYCTGSYYGMDYWGQGTSVTVSS

vl_sequence: >-
  DIQMTQSPSSLSASLGERVSLTCRASQDIRNYLNWYQQKPDGTVKLLIYYTSRLHSGVPSRFSGSGS
  GTDYSLTISNLEQEDIATYFCQQGNTLPWTFGGGTKLEIK

# CDR definitions (IMGT numbering, approximate)
cdrs:
  cdr_h1: GFTFSDYW
  cdr_h2: IRLKSNNYATHYAESVKG
  cdr_h3: GSYYGMDY
  cdr_l1: RASQDIRNYL
  cdr_l2: YTSRLHS
  cdr_l3: QQGNTLPWT

# Humanization
humanization:
  suggested_vh_framework: IGHV1-69*01
  suggested_vl_framework: IGKV3-20*01

  # Humanized VH
  humanized_vh: >-
    EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMNWVRQAPGKGLEWVAEIRLKSNNYATHYAESVKG
    RFTISRDNAKNSLYLQMNSLRAEDTAVYYCTGSYYGMDYWGQGTLVTVSS

  # Humanized VL
  humanized_vl: >-
    EIVLTQSPATLSLSPGERATLSCRASQDIRNYLNWYQQKPGQAPRLLIYYTSRLHSGIPARFSGSGS
    GTDFTLTISSLEPEDFAVYYCQQGNTLPWTFGQGTKVEIK

# Known variants
variants:
  v9:
    description: Affinity-matured UCHT1 derivative
    reference: Zhu & Carter (1995) J Immunol
    vh_mutations: []  # Specific mutations not publicly available
    vl_mutations: []

# Binding properties
binding:
  target: CD3Îµ
  epitope: Different from OKT3 epitope
  kd_nm: 20  # Approximate
  cross_reactivity:
    human: true
    chimpanzee: true
    cynomolgus: false  # Does NOT cross-react
    mouse: false

# Notes for design
notes:
  - Alternative epitope to OKT3/teplizumab
  - Does NOT cross-react with cynomolgus - not suitable for standard preclinical
  - Parent of visilizumab (development discontinued)
  - Lower affinity than OKT3 - may be suitable without attenuation
